Skip to content

Zevra Therapeutics, Inc. ZVRA Intangible Purchases

Intangible Purchases at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$5M-66.7%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$15M
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$5.25M-69.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0-100%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$10M

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Zevra Therapeutics, Inc.’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s intangible purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s intangible purchases?
Zevra Therapeutics, Inc. (ZVRA) reported intangible purchases of $0 in Q4 2025.
How has Zevra Therapeutics, Inc.'s intangible purchases changed year-over-year?
Zevra Therapeutics, Inc.'s intangible purchases decreased by 100.0% year-over-year, from $1.5M to $0.
What does intangible purchases mean?
Cash spent acquiring intangible assets such as patents, licenses, and other intellectual property.